Pushpa Nyoupane - Kilitch Drugs Company Officer
| KILITCH Stock | 306.10 7.45 2.38% |
Executive
Pushpa Nyoupane is Company Officer of Kilitch Drugs Limited
| Address | 37/39, Ujagar Industrial Estate, Mumbai, India, 400088 |
| Phone | 91 22 6121 4100 |
| Web | https://www.kilitch.com |
Kilitch Drugs Management Efficiency
The company has return on total asset (ROA) of 0.0566 % which means that it generated a profit of $0.0566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0832 %, meaning that it generated $0.0832 on every $100 dollars invested by stockholders. Kilitch Drugs' management efficiency ratios could be used to measure how well Kilitch Drugs manages its routine affairs as well as how well it operates its assets and liabilities. The Kilitch Drugs' current Intangible Assets is estimated to increase to about 208.1 M, while Total Assets are projected to decrease to under 1.7 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Aman Gupta | Tata Communications Limited | 45 | |
| Sindoori Reddy | Apollo Hospitals Enterprise | 42 | |
| Dasaratha Reddy | Apollo Hospitals Enterprise | 69 | |
| Surendranath Mantena | Medplus Health Services | N/A | |
| S Krishnan | Apollo Hospitals Enterprise | 55 | |
| Ganesh Karuppannan | Blue Jet Healthcare | N/A | |
| Hemant Auti | Pritish Nandy Communications | N/A | |
| Vimalendu Singh | Blue Jet Healthcare | N/A | |
| Shashwat Nigam | Entero Healthcare Solutions | N/A | |
| Sujit Mahato | Medplus Health Services | N/A | |
| Pathmal Gunawardana | Tata Communications Limited | N/A | |
| Kandasamy Vairaperumal | Medplus Health Services | N/A | |
| Krishnan Akhileswaran | Apollo Hospitals Enterprise | 49 | |
| MD BSc | Apollo Hospitals Enterprise | 67 | |
| Kishor Palkar | Pritish Nandy Communications | N/A | |
| Shobana Kamineni | Apollo Hospitals Enterprise | 64 | |
| Chebolu Ram | Entero Healthcare Solutions | N/A | |
| Archana Arora | Blue Jet Healthcare | 55 | |
| Imtiaz Chougle | Pritish Nandy Communications | N/A | |
| Mysore Madhusudhan | Tata Communications Limited | 61 | |
| Mansi Somvanshi | Tata Communications Limited | N/A | |
Management Performance
| Return On Equity | 0.0832 | ||||
| Return On Asset | 0.0566 |
Kilitch Drugs Limited Leadership Team
Elected by the shareholders, the Kilitch Drugs' board of directors comprises two types of representatives: Kilitch Drugs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kilitch. The board's role is to monitor Kilitch Drugs' management team and ensure that shareholders' interests are well served. Kilitch Drugs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kilitch Drugs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mukund Mehta, Executive MD | ||
| Bhavin BPharm, Wholetime Director | ||
| LLB BCom, Executive MD | ||
| Sunil Jain, Chief Officer | ||
| Mira Mehta, Managing Director | ||
| Pushpa Nyoupane, Company Officer | ||
| Rajesh Khatri, General Administration | ||
| Tajouddin Ansari, VPMarketing Operation |
Kilitch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kilitch Drugs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0832 | ||||
| Return On Asset | 0.0566 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 4.59 B | ||||
| Shares Outstanding | 16.08 M | ||||
| Shares Owned By Insiders | 74.84 % | ||||
| Price To Book | 2.79 X | ||||
| Price To Sales | 3.29 X | ||||
| Revenue | 1.54 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Kilitch Stock
Kilitch Drugs financial ratios help investors to determine whether Kilitch Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kilitch with respect to the benefits of owning Kilitch Drugs security.